THTPA抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10063(THTPA Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P10063(THTPA Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

The THTPA antibody, likely referring to thyroid peroxidase (TPO) antibody, is an autoantibody targeting thyroid peroxidase, a key enzyme in thyroid hormone synthesis. TPO antibodies are central to autoimmune thyroid disorders, such as Hashimoto's thyroiditis and Graves' disease. In Hashimoto's, they contribute to gland destruction by triggering immune-mediated inflammation, leading to hypothyroidism. In Graves' disease, they may coexist with TSH receptor antibodies, though their role here is less direct.

Clinically, TPO antibody detection aids in diagnosing autoimmune thyroiditis, especially when thyroid function tests are ambiguous. Elevated levels are also prognostic markers; for instance, in euthyroid individuals, they indicate higher risks of developing overt hypothyroidism. During pregnancy, their presence is linked to postpartum thyroiditis and potential adverse outcomes like miscarriage or preterm birth.

Testing involves immunoassays, with titers correlating to disease severity. While not targeted therapeutically, their detection guides management, such as thyroid function monitoring or levothyroxine initiation in subclinical hypothyroidism. Research continues to explore their pathogenic mechanisms, including molecular mimicry or genetic susceptibility (e.g., HLA-DR variants). Overall, TPO antibodies serve as critical biomarkers in understanding and managing thyroid autoimmunity.